Veletri patents expiration

VELETRI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598227 ACTELION Epoprostenol formulation and method of making thereof
Feb, 2027

(3 years from now)

US8318802 ACTELION Epoprostenol formulation and method of making thereof
Mar, 2027

(3 years from now)

Veletri is owned by Actelion.

Veletri contains Epoprostenol Sodium.

Veletri has a total of 2 drug patents out of which 0 drug patents have expired.

Veletri was authorised for market use on 27 June, 2008.

Veletri is available in injectable;injection dosage forms.

The generics of Veletri are possible to be released after 15 March, 2027.

Drugs and Companies using EPOPROSTENOL SODIUM ingredient

Market Authorisation Date: 27 June, 2008

Treatment: NA


How can I launch a generic of VELETRI before it's drug patent expiration?
More Information on Dosage

VELETRI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic